Skip to main content
NCBI home page
Sexually Transmitted Infections logoLink to Sexually Transmitted Infections
. 2000 Oct;76(5):386–392. doi: 10.1136/sti.76.5.386

Willingness to participate in HIV-1 vaccine trials among young Thai men

R Jenkins 1, K Torugsa 1, L Markowitz 1, C Mason 1, V Jamroentana 1, A Brown 1, S Nitayaphan 1
PMCID: PMC1744201  PMID: 11141858

Abstract

Objectives: Willingness to participate in HIV-1 vaccine trials and associated factors were investigated in a sample of 2670 Royal Thai Army conscripted recruits.

Methods: Self administered questionnaires were used. Data were collected during the final visit of a longitudinal cohort study of HIV-1 epidemiology. Cross sectional analysis of data from this visit was performed.

Results: 32% of the respondents reported they would "definitely" join an HIV-1 vaccine trial. Greater willingness was associated with perceived risk of HIV-1 infection and a desire to help Thai society, although tangible incentives and intentions to reduce condom use in a vaccine trial also were associated with increased willingness. Concerns about physical harm and anticipated social pressure from family not to join were the most substantial impediments to willingness. Concerns about "social harm" (for example, participation would give appearance of having AIDS virus, a partner might refuse sex) also appeared to inhibit interest in joining trials and approached significance.

Conclusions: Willingness to participate was somewhat greater than in other investigations of non-injection drug user (IDU) cohorts in Thailand, with fewer concerns expressed about physical harm. Motivations appear to involve tradeoffs among perceived risk, anticipated social pressure, altruism, and tangible rewards. The absence of significant problems associated with vaccine trials to date, along with the presence of educational interventions in the study may help explain the lower level of concerns here relative to other Thai studies.

Key Words: HIV; vaccine; Thailand

Full Text

The Full Text of this article is available as a PDF (129.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartholow B. N., MacQueen K. M., Douglas J. M., Jr, Buchbinder S., McKirnan D., Judson F. N. Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Oct 1;16(2):108–115. doi: 10.1097/00042560-199710010-00006. [DOI] [PubMed] [Google Scholar]
  2. Celentano D. D., Beyrer C., Natpratan C., Eiumtrakul S., Sussman L., Renzullo P. O., Khamboonruang C., Nelson K. E. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. AIDS. 1995 Sep;9(9):1079–1083. doi: 10.1097/00002030-199509000-00015. [DOI] [PubMed] [Google Scholar]
  3. Celentano D. D., Beyrer C., Natpratan C., Eiumtrakul S., Sussman L., Renzullo P. O., Khamboonruang C., Nelson K. E. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. AIDS. 1995 Sep;9(9):1079–1083. doi: 10.1097/00002030-199509000-00015. [DOI] [PubMed] [Google Scholar]
  4. Celentano D. D., Bond K. C., Lyles C. M., Eiumtrakul S., Go V. F., Beyrer C., na Chiangmai C., Nelson K. E., Khamboonruang C., Vaddhanaphuti C. Preventive intervention to reduce sexually transmitted infections: a field trial in the Royal Thai Army. Arch Intern Med. 2000 Feb 28;160(4):535–540. doi: 10.1001/archinte.160.4.535. [DOI] [PubMed] [Google Scholar]
  5. Celentano D. D., Nelson K. E., Suprasert S., Eiumtrakul S., Galai N., Kuntolbutra S., Wright N., Theetranont C. Dynamics of risk behavior for HIV infection among young Thai men. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 1;10(4):477–483. doi: 10.1097/00042560-199512000-00012. [DOI] [PubMed] [Google Scholar]
  6. Chesney M. A., Chambers D. B., Kahn J. O. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Dec 1;16(4):266–271. doi: 10.1097/00042560-199712010-00007. [DOI] [PubMed] [Google Scholar]
  7. Graham B. S., McElrath M. J., Connor R. I., Schwartz D. H., Gorse G. J., Keefer M. C., Mulligan M. J., Matthews T. J., Wolinsky S. M., Montefiori D. C. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis. 1998 Feb;177(2):310–319. doi: 10.1086/514209. [DOI] [PubMed] [Google Scholar]
  8. Hom D. L., Johnson J. L., Mugyenyi P., Byaruhanga R., Kityo C., Louglin A., Svilar G. M., Vjecha M., Mugerwa R. D., Ellner J. J. HIV-1 risk and vaccine acceptability in the Ugandan military. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 15;15(5):375–380. doi: 10.1097/00042560-199708150-00008. [DOI] [PubMed] [Google Scholar]
  9. Jenkins R. A., Temoshok L. R., Virochsiri K. Incentives and disincentives to participate in prophylactic HIV vaccine research. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 May 1;9(1):36–42. [PubMed] [Google Scholar]
  10. Koblin B. A., Heagerty P., Sheon A., Buchbinder S., Celum C., Douglas J. M., Gross M., Marmor M., Mayer K., Metzger D. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998 May 7;12(7):785–793. doi: 10.1097/00002030-199807000-00015. [DOI] [PubMed] [Google Scholar]
  11. Koblin B. A., Taylor P. E., Avrett S., Stevens C. E. The feasibility of HIV-1 vaccine efficacy trials among gay/bisexual men in New York City: Project ACHIEVE. AIDS Community Health Initiative Enroute to the Vaccine EFfort. AIDS. 1996 Nov;10(13):1555–1561. doi: 10.1097/00002030-199611000-00015. [DOI] [PubMed] [Google Scholar]
  12. MacQueen K. M., Vanichseni S., Kitayaporn D., Lin L. S., Buavirat A., Naiwatanakul T., Raktham S., Mock P., Heyward W. L., Des Jarlais D. C. Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand. J Acquir Immune Defic Syndr. 1999 Jul 1;21(3):243–251. doi: 10.1097/00126334-199907010-00010. [DOI] [PubMed] [Google Scholar]
  13. Meyers K., Metzger D. S., McLellan A. T., Navaline H., Sheon A. R., Woody G. E. Will preventive HIV vaccine efficacy trials be possible with female injection drug users? J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15;10(5):577–585. [PubMed] [Google Scholar]
  14. Nelson K. E., Celentano D. D., Eiumtrakol S., Hoover D. R., Beyrer C., Suprasert S., Kuntolbutra S., Khamboonruang C. Changes in sexual behavior and a decline in HIV infection among young men in Thailand. N Engl J Med. 1996 Aug 1;335(5):297–303. doi: 10.1056/NEJM199608013350501. [DOI] [PubMed] [Google Scholar]
  15. Phanuphak P., Teeratakulpixarn S., Sarangbin S., Nookhai S., Ubolyam S., Sirivichayakul S., Leesavan A., Forrest B. D., Hanson C. V., Li M. International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand. Asian Pac J Allergy Immunol. 1997 Mar;15(1):41–48. [PubMed] [Google Scholar]
  16. Pitisuttithum P., Migasena S., Laothai A., Suntharasamai P., Kumpong C., Vanichseni S. Risk behaviours and comprehension among intravenous drug users volunteered for HIV vaccine trial. J Med Assoc Thai. 1997 Jan;80(1):47–50. [PubMed] [Google Scholar]
  17. Tello J., Soong S. J., Hunter B., Meriwether R., Hook E. W., 3rd, Mulligan M. J. HIV vaccine acceptance among heterosexual clients of a sexually transmitted diseases clinic. Am J Med Sci. 1998 Jan;315(1):11–16. doi: 10.1097/00000441-199801000-00003. [DOI] [PubMed] [Google Scholar]

Articles from Sexually Transmitted Infections are provided here courtesy of BMJ Publishing Group

RESOURCES